GemPharmatech Co., Ltd. (SHA:688046)
China · Delayed Price · Currency is CNY 17.43
-0.16 (-0.91%)
At close: Feb 12, 2026
GemPharmatech Revenue
In the year 2025, GemPharmatech had annual revenue of 793.25M CNY with 15.49% growth. GemPharmatech had revenue of 217.68M in the quarter ending December 31, 2025, with 22.90% growth.
Revenue
793.25M
Revenue Growth
+15.49%
P/S Ratio
8.80
Revenue / Employee
502.70K
Employees
1,578
Market Cap
6.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 793.25M | 106.42M | 15.49% |
| Dec 31, 2024 | 686.84M | 64.65M | 10.39% |
| Dec 31, 2023 | 622.19M | 105.64M | 20.45% |
| Dec 31, 2022 | 516.55M | 122.76M | 31.17% |
| Dec 31, 2021 | 393.79M | 131.87M | 50.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Novogene | 2.17B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Wuhan Keqian Biology Co.,Ltd | 1.01B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 789.45M |
| Zhejiang Ausun Pharmaceutical | 751.12M |